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Quality Improvement Program (NSQIP) database. Multi-
variable logistic regression analysis was performed to iden-
tify preoperative factors associated with 30-day mortality
and graft failure.
Results: Of the 493 patients who underwent AFB, 89
(18.05%) received a VG and 404 (81.95%) received a PG.
Thirty-day mortality rates for patients receiving VG and PG
were 2.25% and 6.19%, respectively (P  .14) and graft
failure rates were 6.74% and 2.97%, respectively (P  .08).
On multivariate analysis, there was no difference in 30-day
mortality (odds ratio (OR)0.53; 95% confidence interval
(CI) 0.11-2.56) or graft failure rate (OR2.38; 0.77-
7.34) for patients receiving VG or PG for AFB.Of the 1219
patients who underwent FFB, 251(20.59%) received a VG
and 968 (79.41%) received a PG. Thirty-day mortality rates
for patients receiving VG and PG were 1.99% and 1.03%,
respectively (P .21) and graft failure rates were 3.98% and
1.65%, respectively (P  .04). On multivariate analysis,
there was no difference in 30-day mortality (OR1.45;
CI 0.38-5.59) or graft failure rate (OR2.19; CI 0.94-
5.08) for patients receiving VG or PG for FFB.
Conclusions: Thirty-day mortality and graft failure
rate are independent of the type of conduit used in patients
undergoing extra-anatomic arterial bypass.
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Objectives: To compare early and follow-up results of
below-knee bypasses performed with a bioactive heparin-
treated ePTFE graft and with autologous saphenous vein
(ASV) in patients with critical limb ischemia in a multicen-
tric retrospective registry involving eight Italian and Amer-
ican vascular centres.
Methods: Over a nine year period, ending in 2010, a
heparin bonded prosthetic graft (Propaten Gore-Tex®,
W.L. Gore & Associates Inc, Flagstaff, AZ) was implanted
in 461 patients undergoing below-knee revascularization
for critical limb ischemia in seven Italian and one American
hospitals (HePTFE group). In the same period of time in
these eight centres 376 below-knee bypasses with ipsilateral
ASV in patients with critical limb ischemia were performed
(ASV group). Early (30 days) results were analyzed in
terms of graft patency, major amputation rates and mortal-
ity. Follow-up results were analyzed in terms of primary and
secondary graft patency, limb salvage and survival.
Results: Early graft thrombosis occurred in 52 patients
(33 in HePTFE group and 19 in ASV group); there were
26 early major amputations (19 in HePTFE group and 7 in
ASV group), with 30-day major amputation rates of 3.9%
and 1.9%, respectively (P .09).Mean duration of follow-up
was 27.1  22.4 months. Primary patency rate at 48
months was significantly better in ASV group (61.8%) than
in HePTFE group (38.5%; P  .001, log rank 19.1). The
rates of secondary patency at 48 months were 51.9% in
HePTFE group and 65.9% in ASV group (P .02, log rank
52); the corresponding values in terms of limb salvage and
amputation free-survival rates were 74.4% and 78.9% (P 
.3, log rank 0.9), and 52.9% and 54% (P .6, log rank 0.2),
respectively.
Conclusions: Heparin-bonded ePTFE graft provides
satisfactory early and mid-term results in patients undergo-
ing surgical treatment of critical limb ischemia. While au-
tologous saphenous vein maintains its superiority in terms
of primary and secondary patency, limb salvage rates are
comparable.
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Objectives: This article reports the early human results
of HELP technology in the prevention of major limb
amputation due to ischemia. In short-term aim was to
dilate pre-existing collateral channels and the long-term
aim was to stimulate remodelling and new collateral devel-
opment by increasing endothelial shear stress.
Methods: A pilot study consisted of 20 patients with
critical limb ischemia. These patients had no other option
but major amputation as determined by at least two vascu-
lar surgeons. The ischemic limb was isolated from the
systemic circulation by the use of an implantable, inflatable,
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occlusive cuff. The limbs were hyperperfused through arte-
rial access devices with a pump, producing a nonpulsatile
waveform at 200% to 300% of the mean arterial pressure
(MAP). This was performed intermittently in sessions of 24
to 36 hours and up to a maximum of 74 hours. The primary
end point was avoidance of major amputation. The second-
ary end points were the clinical improvements in rest pain,
ulcer healing, and claudication distance. The objective find-
ings include infrared thermography and ultrasound imag-
ing parameters of the limb.
Results: 39 of 40 connections developed flows 4 to 8
times those supplied to the limb by the normal cardiac
output. There was a progressive decrease in peripheral
resistance. All patients developed a pain-free, warm foot or
handwhilst on the pump in the short-term. In the longterm
at a mean of 22 months (12-54 months), eight of 20
patients (40%) had avoided major amputation and four
more had a delay in amputation of an average of 4 months.
The ankle-brachial index changed from 0.11  0.23 to
0.61 0.38 (P .05). Bleeding, infection, and removal of
the access systems and poor patient selection resulted in the
failures.
Conclusions: In selected cases major amputation may
be avoided by augmenting the collateral circulation of
ischemic limbs using an extracorporeal cardiac pump, oc-
cluding balloons and with an access system providing inter-
mittent pump connections.
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Objectives: In 2009 the Society for Vascular Surgery
(SVS) developed Objective Performance Goals (OPGs) to
assess the safety and efficacy of endovascular treatments of
critical limb ischemia (CLI). We evaluated Laser-assisted
angioplasty (LAA), using the OPGs
Methods: All patients that underwent LAA to treat
CLI between January 2006 and May 2010 were analyzed.
The 30 day safety endpoints of Major Adverse Cardiac
Event (MACE) (i.e. Postoperative Death (POD), Myocar-
dial Infarction (MI ) and Cerebrovascular Accident (CVA),
Amputation rate and Major Adverse Limb Event (MALE)
rate (i.e. thrombosis, thrombectomy, and bypass) were
calculated. The efficacy endpoints were calculated using
Kaplan-Meier life table analysis. These included MALE 
POD, Amputation Free Survival (AFS), and any Re-inter-
vention or above ankle Amputation and Stenosis /occlu-
sion (RAS) calculated at one year. Subsequently, a compar-
ison with the SVSOPGs was made using the student T test.
Results: : Laser assisted angioplasty was used to treat
82 limbs with CLI. The mean age was 72.8 years, with a
mean follow up of 19 months. Tissue loss and gangrene
were the most common indications, in 67 (81.2%) of the
limbs. Safety endpoints were: mortality rate 2.6%, MACE
rate 3.9%, amputation rate 2.4%, and MALE rate of 9.7%.
Efficacy endpoints were MALE  POD 84.1%, Amputa-
tion Free Survival 84.1%, and RAS 39%.Our study cohort
was compared to the SVS OPGs using the Student T test;
MACE 3.9% vs. 5.1% (P  .72), 30 day amputation rate
2.4% vs. 1.3% (P  .43), MALE 9.7% vs. 4.6% (P  .06).
One year outcomes: MALEPOD 84.1% vs. 76.9% (P 
.14), AFS 84.1% vs. 76.5% (P  .14), RAS 39% vs. 46.5%
(P  .21). No statistically significant difference was noted.
Conclusions: Our study demonstrates that the OPGs
are attainable in clinical practice. Moreover, LAAmeets the
safety and efficacy OPGs for endovascular treatment of
CLI.
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Objectives: Local vancomycin treatment has been
shown to decrease sternal wound complication rates.
Whether a similar effect can be achieved at other surgical
sites is unknown. This study investigates the effect of local
vancomycin on inguinal wound complication rates follow-
ing vascular procedures.
Methods: Retrospective analysis was performed on
646 patients who underwent open infra-inguinal and hy-
brid endovascular procedures between 2006 and 2011.
Patients received either pre-operative systemic antibiotics
alone (Group A) or in conjunction with intra-operative
wound application of vancomycin powder and irrigation
(Group B). Wound site infection and dehiscence over a
30-day period were recorded. Fisher exact test and multi-
variate regression analyses were performed.
Results: There were 424 patients in Group A and 222
patients in Group B. Both groups had similar demographics
and distribution of vascular procedures. There was no
significant difference in the 30-day incidence of superficial
and deep wound infections (OR: 0.72, P  .19) or dehis-
cence (OR: 1.2, P  .46) between the two groups after
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